Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Nafamostat Mesilate on Hemodynamic Stability After Reperfusion of the Liver Graft

NCT01001403 is registered in ClinicalTrials.gov with Seoul National University Hospital as lead sponsor.

NCT NCT01001403
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01001403 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Nafamostat Mesilate on Hemodynamic Stability After Reperfusion of the Liver Graft
Lead sponsor
Seoul National University Hospital
Phase
Phase 4
Overall status
Completed
Start date
March 31, 2009
Completion date
April 30, 2010
Enrollment
62 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

liver transplantation, postreperfusion syndrome